Angelini Pharma Deal History & Licensing Activity
Angelini Pharma is a large biotech headquartered in US. Over the past three years, Angelini Pharma has been involved in 6 licensing and acquisition transactions, with a primary focus on Small Molecules (7 deals).
Deals (12mo)
5
Active Trials
0
Top Modality
Small Molecules
Focus Area
Neurology
Angelini Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Angelini Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Catalyst rare neurological disease pipeline | Angelini | Small Molecules | Unknown | acquisition | Jul 1, 2026 |
| Catalyst Pharmaceuticals | Angelini | Other | Unknown | acquisition | Jun 15, 2026 |
| Catalyst Pharmaceuticals rare CNS portfolio | Catalyst Pharmaceuticals | Small Molecules | Approved |
Angelini Pharma Pipeline Focus
Therapeutic areas and modalities where Angelini Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Angelini Pharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Angelini Pharma Licensing & Deal Activity
Angelini Pharma is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, Angelini Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Angelini Pharma include Neurology (7 deals and trials), and Mega Deals (4 deals and trials). In terms of modality, Angelini Pharma has shown particular interest in small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Angelini Pharma and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Angelini Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.